A Pilot of the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment
Status:
Withdrawn
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The investigators propose to conduct a series of N of One (No1) single blinded clinical
trials to pilot the feasibility of using the iron-chelator deferiprone on Mild Cognitive
Impairment (MCI). Chelation therapy has previously been reported to slow the rate of
cognitive decline in Alzheimer's Disease (AD) by 50% in a single human randomized clinical
trial.
Phase:
Early Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio